Key Takeaways
- • Hong Kong Investment Corporation (HKIC), Gobi Partners, and the University of Hong Kong launched Gobi-HKU Fund I to invest in technology start-ups commercializing university research, with initial deployments in robotics and AI-driven drug design companies at launch.
- • HKIC, backed by government reserves and managing HK$62 billion (US$8 billion) as of February 2026, deployed capital into Manifold Tech (spatial intelligence for robotics) and AilsynBio (AI-driven drug design) as the fund's first investments.
- • The fund employs a milestone-based investment approach, deploying smaller initial capital tranches with predetermined commercialization targets that trigger rapid follow-on funding from the earmarked capital pool.
- • HKIC has invested in over 190 projects since its 2022 establishment and continues expanding its innovation ecosystem support through strategic partnerships and networking initiatives, including the recently announced Hong Kong RISC-V Alliance.
- • The partnership represents a three-way collaboration between government investment infrastructure, institutional venture capital, and academic research assets to accelerate university-originated deep technology commercialization.
Summary
Hong Kong Investment Corporation, the government's strategic investment arm, has partnered with venture capital firm Gobi Partners and the University of Hong Kong to establish Gobi-HKU Fund I, formally launched on Tuesday. The fund is structured to identify, fund, and scale technology start-ups emerging directly from HKU's research ecosystem, addressing a key challenge in converting academic breakthroughs into commercial enterprises.
At launch, the fund deployed capital into two portfolio companies: Manifold Tech, which develops spatial intelligence solutions for robotics applications, and AilsynBio, a biotechnology company focused on artificial intelligence-driven drug design and recovery. These initial investments demonstrate the fund's dual focus on hardware and biotech sectors within the broader deep-technology space.
The fund operates under a milestone-based investment methodology, a structured approach that reduces initial capital deployment risk. HKIC and its partners invest a smaller amount in individual projects initially, with the flexibility to rapidly deploy additional capital ("top up") from the fund's reserved pool once predefined commercialization milestones are achieved. This staged capital approach balances portfolio risk while maintaining execution velocity as companies progress toward market validation.
HKIC, established in 2022 with backing from Hong Kong's government reserves, has rapidly scaled its investment activities. As of February 2026, the corporation managed HK$62 billion (US$8 billion) in government funds and had committed capital to over 190 projects across innovation and technology sectors. Clara Chan Ka-chai, HKIC's Chief Executive, emphasized that the fund launch reflects the organization's mandate to foster synergy among investment, industry, academia, research, and government stakeholders. Beyond direct venture investment, HKIC has expanded its ecosystem support through networking activities and strategic alliances, including the recent establishment of the Hong Kong RISC-V Alliance, broadening its role from capital provider to innovation infrastructure builder.
At launch, the fund deployed capital into two portfolio companies: Manifold Tech, which develops spatial intelligence solutions for robotics applications, and AilsynBio, a biotechnology company focused on artificial intelligence-driven drug design and recovery. These initial investments demonstrate the fund's dual focus on hardware and biotech sectors within the broader deep-technology space.
The fund operates under a milestone-based investment methodology, a structured approach that reduces initial capital deployment risk. HKIC and its partners invest a smaller amount in individual projects initially, with the flexibility to rapidly deploy additional capital ("top up") from the fund's reserved pool once predefined commercialization milestones are achieved. This staged capital approach balances portfolio risk while maintaining execution velocity as companies progress toward market validation.
HKIC, established in 2022 with backing from Hong Kong's government reserves, has rapidly scaled its investment activities. As of February 2026, the corporation managed HK$62 billion (US$8 billion) in government funds and had committed capital to over 190 projects across innovation and technology sectors. Clara Chan Ka-chai, HKIC's Chief Executive, emphasized that the fund launch reflects the organization's mandate to foster synergy among investment, industry, academia, research, and government stakeholders. Beyond direct venture investment, HKIC has expanded its ecosystem support through networking activities and strategic alliances, including the recent establishment of the Hong Kong RISC-V Alliance, broadening its role from capital provider to innovation infrastructure builder.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.